Fasting in managment of psoriasis
Not Applicable
- Conditions
- Health Condition 1: L400- Psoriasis vulgaris
- Registration Number
- CTRI/2020/12/029472
- Lead Sponsor
- IADV
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Chronic plaque psoriasis candidate for systemic therapy
Body surface area >10% or PASI >10 or DLQI >10
Exclusion Criteria
Contraindication to methotrexate or fasting
pregnancy, lactation
Uncontrolled diabetes mellitus
Chronic infection like tuberculosis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in psoriasis assessment severity assessment (PASI)Timepoint: 12 weeks and 24 weeks
- Secondary Outcome Measures
Name Time Method Biomarkers for atherosclerosis <br/ ><br>HDL, CCRP, IL-6, VEGFTimepoint: 28 weeks;metabolic parameters <br/ ><br>Weight <br/ ><br>Waist size <br/ ><br>Blood sugar fasting and post prandial <br/ ><br>lipid profileTimepoint: 16 weeks, 28 weeks